*仅供医学专业人士阅读参考
临床决策,可以更简单
[1]McMurray JJV,Östergren J,Swedberg K,Granger CB,Held P,ichelson EL,Olofsson B,Yusuf S,PfefferA;CHARM Investigators and Committees.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial.Lancet(2003)362,767–71.
[2]PfefferA,cMurray JJV,Velazquez EJ,Rouleau J-L,Køber L,aggioni AP,Solomon SD,Swedberg K,Van de Werf F,White H,Leimberger JD,Henis,Edwards S,Zelenkofske S,SellersA,Califf RM;Valsartan in Acuteyocardial Infarction Trial Investigators.Valsartan,captopril,or both inyocardial infarction complicated by heart failure,left ventricular dysfunction,or both.N Engl Jed(2003)349,1893–1906.
[3]Jacobsen P,Andersen S,Rossing K,Jensen BR,Parving H-H.Dual blockade of the renin-angiotensin system versusaximal recommended dose of ACE inhibition in diabetic nephropathy.Kidney Int(2003)63,1874–80.
[4]Izzo JL,WeinbergS,Hainer JW,Kerkering J,Tou CKP.Antihypertensive efficacy of candesartan-lisinopril in combination vs.up-titration of lisinopril:the AMAZE trials.J Clin Hypertens(Greenwich)(2004)6,485–93.
[5]ONTARGET Investigators,Yusuf S,Teo KK,Pogue J,Dyal L,Copland I,Schumacher H,Dagenais G,Sleight P,Anderson C.Telmisartan,ramipril,or both in patients at high risk for vascularevents.N Engl Jed(2008)358,1547–59.
[6]ann JFE,Schmieder RE,cQueen,Dyal L,Schumacher H,Pogue J,Wang X,aggioniA,Budaj A,Chaithiraphan S,Dickstein K,Keltai,etsärinne K,Oto A,Parkhomenko A,Piegas LS,Svendsen TL,Teo KK,Yusuf S;ONTARGET investigators.Renal outcomes with telmisartan,ramipril,or both,in people at high vascular risk(the ONTARGET study):aulticentre,randomised,double-blind,controlled trial.Lancet(2008)372,547–53.
[7]Guthrie RM.Review of ONTARGET:treating patients at high risk for vascular events with telmisartan,ramipril,or both.Postgraded(2009)121,202–4.
本文来源:医学界临床药学频道 本文作者:红油辣酱 责任编辑:小当当
联系客服